FDA Approves Celcuity's Gedatolisib in Combination Therapy for Breast Cancer
The U.S. Food and Drug Administration (FDA) has approved Celcuity’s Revtorpyk (gedatolisib) in combination with fulvestrant, with or without palbociclib, for the treatment of HR+/HER- breast cancer following one line of endocrine therapy.
Tickers: $CELC